No Data
No Data
Tharimmune Files to Sell 1.44M Shares of Common Stock for Holders
Tharimmune Announces Phase 2 Study Plan for TH104
Tharimmune Provides Business Update, Corporate Highlights
Express News | Tharimmune: Plan to Report Preliminary Results From Phase 2 Trial in Late 2025
Express News | Tharimmune: Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis
Trending Stocks Today | MEDIROM Healthcare Technologies Soars 97.04% Post-Market
No Data